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Type 1 diabetes (T1D) is caused by autoimmune destruction of the insulin-producing β-cells of the islets of Langerhans. One still open
question is where naive islet-reactive T cells encounter antigens and become stimulated. In this report we have re-examined the expression of
MHC class II (MHCII) genes in human islets to further explore the possibility that non-professional antigen presenting cells (APCs) within islets
contribute to autoimmunity. Since development of T1D has been linked to viral infections, we also studied ex-vivo MHCII expression in response
to interferon-α (IFNα) in islet tissue and in different APCs. The findings are: first, MHCII genes expression in human islets is linked with the
expression of the class II transactivator isoform transcribed from the promoter IV, similar to that described in non-professional APCs. Second,
there is IFNα-mediated lineage-specific regulation of MHCII genes expression, seen as a decrease in the accumulation of MHCII transcripts in
pancreatic islets opposite to an increase in dendritic cells and B-lymphoblastoid cell lines. Third, there is allele-specific regulation of the HLA-
DQA1 gene by IFNα in islet tissue. These findings may begin to explain the molecular events that create favorable conditions for organ-specific
autoimmunity and explain the incomplete penetrance of T1D susceptibility alleles.
© 2006 Elsevier B.V. All rights reserved.Keywords: Human; Diabetes; MHC; Gene regulation; Interferon-α; Transplantation1. Introduction
It is well known that IFNα influences the innate and adaptive
immune system and has an important role in the pathogenesis of
several autoimmune diseases [1]. For many decades progression
of T1D has been linked to viral infections and recently IFNα
presence has been shown to correlate with β-cell injury in both
animal models and recent-onset T1D [2–4]. It has been
hypothesized that the activation of toll receptors by double-
stranded RNA or poly-IC (viral mimic) and subsequent in-
duction of IFNα production may activate or accelerate immune-
mediated β cell destruction. Treatment with exogenous IFNα,⁎ Corresponding author. Institute of Genetics and Biophysics Adriano
Buzzati-Traverso, CNR, via P. Castellino 111, Naples 80131, Italy.
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doi:10.1016/j.bbadis.2006.05.001however, has been reported to be protective against T1D de-
velopment in nonobese diabetic (NOD) mice [5], as well as to
preserve residual β-cell function in patients with recent onset
T1D [6]. Similarly, the prolonged administration of IFNα has
been shown to delay islets rejection in a subset of mice
recipients of islets allografts [7]. Currently, a clinical trial with
T1D patients sponsored by the National Institute of Diabetes
and Digestive and Kidney Diseases (NIDDK) (Title: Ingested
Interferon Alpha: Prolongation or Permanence of the “Honey-
moon” Phase in Newly Diagnosed Diabetes Mellitus. Number:
01-DK-0249) is testing the possible protective effect of IFNα
given early in the disease. Nevertheless the data on protection of
β-cells mediated by this cytokine are still very controversial and
need a careful evaluation before being considered conclusive.
Recently, using oligonucleotide chips for gene expression
profiling, we have demonstrated the presence of MHCII-specific
transcripts in human islet tissue from cadaveric normal donors [8]
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tissue after 48 h of culture in presence of IFNα. The role of type I
IFNs as modulators of MHCII genes expression has been studied
in a variety of systems, however the resulting data have been quite
variable and have not allowed a uniform definition. The only
consensus view is that, for many cell types, type I IFNs block the
induction of MHCII expression by interferon-γ (IFNγ) [9].
The process of autoimmune destruction of the β-cells, dis-
tinctive of T1D, eventually results in the failure of the insulin
secretory capacity and dependence on exogenous insulin for
survival [10]. T1D is characterized by the presence of antibody
(humoral) and T-cell (cellular) responses to islet proteins. His-
tological analysis of sections from the pancreas from patients
with T1D reveals the presence of potential immune effector
cells (e.g., presence of CD4+ cells) that are not present in a
healthy or a type 2 diabetic pancreas [11]. The infiltrates are
limited to insulin-containing islets, includes activated lympho-
cytes, and contain deposition of antibodies and components of
the complement system. The idea that multiple islet molecules
are the target of autoimmunity in human and animal models of
T1D [10,12] is well accepted. Between the multiple candidate
antigens indicated as responsible for the initiation and the
maintenance of T1D auto-immune response in diabetes, one of
the more accredited is insulin itself [13,14].
Of the known genetic factors cooperating in the development
of T1D, MHCII genes exhibit the strongest association with
disease susceptibility [15]. Extensive work has identified HLA-
DQ8 and HLA-DQ2 haplotypes in humans, and I-Ag7 allele in
NOD mice, as major risk factors for increased susceptibility to
T1D [16]. Presentation of endogenous peptides in the context of
permissive MHC molecules encoded by these alleles is
considered to select a T cell repertoire capable of subsequently
recognizing diabetogenic peptides and initiate the destructive
autoimmune response through incompletely understood mech-
anisms. The presence in pancreatic islets of resident MHCII-
positive cells acting directly as APCs to β-cell reactive CD4+ T
cells has been a controversial topic in the field for more than a
decade [17,18]. Although β-cells may not express MHCII
genes, the expression of MHCII genes has been found within
the islet cell mass in T1D-affected humans [19,20] and in NOD
mice [21]. In some studies it has been shown that islet resident
cells may be induced to express MHCII when cultured with
IFNγ plus Tumor Necrosis Factor α or β [22]. In rat studies, it
has been demonstrated that naïve T cells react against islet
allografts in a mixed culture of islets and Peripheral Blood
Mononuclear Cells (PBMCs) [23] and more recent data [24]
demonstrate the immunogenic properties of human islet pre-
parations of clinical norm. HLA-DR matching is accompanied
by lack of immune reactivity against the islet preparation.
The functional significance of MHCII expression by endothe-
lial cells (EC) and their role as APCs, have been suggested to be
important in augmenting the recruitment of antigen-specific T
cells into tissues [25,26]. In NOD mice, it has been shown that
pancreatic endothelial cells are able to cross-present at least oneβ-
cell specific candidate auto-antigen, insulin, for antigen-driven
homing of specific CD8+ Tcells to islets [27]. It has been reported
that vascular endothelium also expresses costimulatory moleculesnecessary for antigen presentation, especially under inflammatory
conditions [28] and that in vitro, human T lymphocytes proliferate
after coculture with vascular endothelium [29]. It is reasonable to
infer that during an inflammatory process involving islets, the
resident endothelial cells (ECs) expressing MHCII molecules can
present relevant epitopes of islet autoantigens toCD4+Tcells, and
therefore contribute to the development of autoimmune diabetes.
MHCII expression is mainly regulated at the level of tran-
scription [30]. A number of known factors bind cooperatively to
well characterized conserved sequence elements in the promoters
of MHCII genes and form a highly stable macromolecular nu-
cleoprotein complex referred to as theMHCII enhanceosome [31].
The class II transactivator (CIITA) (encoded by the MHC2TA
gene) is a non-DNA-binding coactivator that interact with the
enhanceosome and is essential for the expression ofMHCII genes
[30,32–34]. Differently from the expression of the enhanceosome
components that seems to be more or less ubiquitous and appar-
ently independent from IFNγ-induction, CIITA exhibits a cell-
type-specific, cytokine-inducible and differentiation-stage-specif-
ic expression. This expression shows a pattern that precisely
parallels that of MHCII genes [30] and a level of transcript
accumulation that correlates with that of MHCII genes [35,36]. In
particular, it has been proposed that repression of the CIITA gene
plays a key role in the down-regulation of MHCII expression in
various physiological and pathological situations. Notable ex-
amples for these situations include the regulation of immune
responses for avoiding autoimmunity as well as the acquired
mechanisms for the evasion of the immune surveillance by tumor
cells and by various pathogens [34]. Three different isoforms of
CIITA with different functions have been identified; each is
transcribed by a distinct promoter. Generally promoter I (for the
transcription of the CIITApI isoform) is considered to be active in
dendritic cells (DCs) and activated macrophages, while promoter
III (for the transcription of the CIITApIII isoform) operates in B
cells and activated Tcells. Promoter IV (for the transcription of the
CIITApIV isoform) is essential for responsiveness to IFNγ in
different APCs [37] and has been described as constitutively
active in thymic epithelial cells [38] and renal microvascular ECs
[39]. The role in susceptibility to inflammatory diseases ofMHCII
molecules is commonly associated to their attributes in the binding
and presentation of peptides to T cells. However, there are emer-
gent concepts taking in account that the level of MHC II gene
expression, strictly depending on the variability in the modulation
of the expression of MHCII genes [40,41], is also a risk factor for
such diseases. Recent genetic data showed that rat strain-
dependent differences in expression of MHCII molecules are
associated to polymorphisms in the promoter of the MHC2TA
gene and that the expression of one of the CIITApIII isoform
variant is associated with lower induction of class II genes and
susceptibility to rheumatoid arthritis, multiple sclerosis and myo-
cardial infarction [42].
The HLA-DQAl and HLA-DQBl genes are each significantly
polymorphic and, respectively, encode the α and β chains of the
DQ molecule. Both the DQ haplotype (in cis or trans) and a
possible allele dosage effect influence the cell surface composi-
tion of these heterodimers to generate the diabetogenic phenotype
[41]. The allele-specificity of the inducible expression of HLA-
Table 1
List of primers used in qRT-PCR experiments
Gene symbol Primer position Primer sequence (5′→3′)
GAPDH Forward AACGGATTTGGTCGTATTGGGC
Reverse TCGCTCCTGGAAGATGGTGATG
IRF7 Forward GCAAGGTGTACTGGGAGGTG
Reverse CGAAGCCCAGGTAGATGGTA
HLA-DRA Forward GGACAAAGCCAACCTGGAAA
Reverse AGGACGTTGGGCTCTCTCAG
HLA-DQA1 Forward GGTGTAAACTTGTACCAGT
Reverse GGAGACTTGGAAAACACT
HLA-DQA1*01 Forward CGGTGGCCTGAGTTCAGCAA
Reverse GGAGACTTGGAAAACACTGTGACC
HLA-DQA1*02 Forward AAGTTGCCTCTGTTCCACAGAC
Reverse GGAGACTTGGAAAACACTGTGACC
HLA-DQA1*03 Forward CTCTGTTCCGCAGATTTAGAAGA
Reverse GGAGACTTGGAAAACACTGTGACC
HLA-DQA1*05 Forward TGGTGTTTGCCTGTTCTCAGAC
Reverse GGAGACTTGGAAAACACTGTGACC
CIITA Forward CCGACACAGACACCATCAAC
Reverse CTTTTCTGCCCAACTTCTGC
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cytes of normal and T1D affected individuals [43]. This regulated
expression, resulting in differential accumulation of allele-spe-
cific transcripts, depends upon controlling elements located in the
polymorphic upstream regulatory regions of this gene [41] and is
modulated by environmental signals such as cytokines rather than
by constitutive mechanisms [43,44].
In this report we have re-examined the expression of MHCII
genes in response to IFNα in human islet tissue and in different
APCs lineages to further explore the hypothesis that non profes-
sionalAPCswithin islet tissuemight contribute to themechanisms
of the activation and maintenance of anti β-cell autoimmunity. To
this end, we first studied lineage-specific modulation of MHCII
expression to better understand the apparent protective role of
IFNα in during immune attack of islet beta cells. And second,with
the rationale that the IFNα-mediated allelic-specific regulation of
DQA1 expression in the pancreatic islets might play a role in the
organ specific autoimmunity leading to T1D, we measured the
variability in the amount of allele-specific mRNA in samples
heterozygous for HLA-DQA1 locus. To insure a sensitive and
reproducible mRNA quantitation we used the RealTime technol-
ogy for our quantitative RT-PCR (qRT-PCR) assays. Finally, we
sought to link the expression of CIITA-specific transcripts in ex
vivo cultivated pancreatic islets with the expression of MHCII
genes.
2. Materials and methods
2.1. Tissues, cells and cultures
The islet and exocrine pancreas tissue used in these studies were obtained with
institutional review board approval. Pancreas digestion and islet isolation were
performed using minor modifications of the Edmonton purification protocol
previously described by Shapiro et al. [45]. Briefly, islets were isolated by perfusing
the pancreatic duct with a cold enzyme mixture containing Liberase HI (Roche,
Indianapolis, IN) [46]. Tissue was then transferred to a Ricordi chamber and
separated by gentle mechanical agitation and enzymatic digestion at 37 °C. Islets
were purified with the use of discontinuous gradients of Ficoll-diatrizoic acid [47]
in an aphaeresis system (model 2991, Cobe Laboratories, Lakewood, CO).
Glucose-stimulated release of insulin by isolated isletswas performed as previously
described [8,48], following a 24 h incubation at 37 °C in CMRL 1066 medium
(GibcoBRL) with 2.5% (wt/vol) human serum albumin and 25 mmol HEPES
buffer. The mean values of the insulin stimulation index assay performed on the
islet samples used in these studies was N3.4. The determination of islet cell mass,
viability, and purity were performed as previously described [8]. Themean number
of the total islet equivalents (IEQs) isolated per preparation was of 315,000
(190,000–440,000) showing a purity N94% and a viability N91%. After 4 days of
culture, each islet sample was split in three flasks (60,000IEQs/20 ml) and either
IFNα-2b (1000 U/ml), IFNγ (1000U/ml; R&DSystems,Minneapolis,MN), or no
IFN was added to the medium. The amount of IFNα and IFNγ used in our culture
was based on the dosage used in our previous studies [8], ensuring that the viability
after culture was still greater than 90%. After 48 h of culture all the islets were
collected for the RNA preparation.
Five HLA-defined B-Lymphoblastoid Cell Lines (B-LCLs) (NACR.0103,
NACR.0379, NACR.0361, NACR.0112, NACR.0376) were obtained from the
NMDP/ASHI Cell Repository1 and cultured as per their recommendations. Two1 The NMDP/ASHI Cell Repository is supported by funding from the Office
of Naval Research and ASHI. The views expressed in this article are those of
the authors and do not reflect the official policy or position of the Department
of Navy, DoD, the U.S. Government, NMDP, ASHI or members of the NMDP/
ASHI Cell Repository Steering Committee.cell culture flasks were cultured 48 h in the presence or absence of IFNα-2b
(1000 U/ml). Other cultures were incubated for 5 days using the same scheme of
IFNα stimulation. After the culture the cells were collected for the RNA
preparation.
For the generation of DCs, monocytes were obtained by plastic adherence
from PBMCs of healthy donors. As already described [49], adherent cells were
cultured for 3 days in serum free medium with Granulocyte-Macrophage
Colony-Stimulating Factor (GM-CSF) (50 ng/ml) or GM-CSF (50 ng/ml) with
IFNα-2b (10,000 U/ml), on day three, the medium replaced with fresh medium
supplemented with additional GM-CSF or GM-CSF with IFNα-2b. To confirm
that dendritic cells had been generated, before RNA preparation, their immuno-
phenotype was tested on day six, using the FACSCalibur flow cytometer and the
CellQuest software (both from Becton Dickinson, San Jose, CA). The mono-
clonal antibodies panel used included fluorochrome-conjugated antibodies to
CD14, CD83, HLA-DR, CD80, and CD86. Staining, washing, and analysis
were performed as per the manufacturer's recommendations (Becton Dickinson)
[49,50].
2.2. RNA isolation
Total cellular RNA from cell cultures was extracted, isolated, and purified
using TRIZOL Reagent (GibcoBRL) according to the manufacturer's
recommendations. All RNA extractions were performed using RNase/DNase-
free laboratory ware. RNA was quantified and assessed for purity by electro-
phoresis on a 1.6% agarose gel and UV spectrophotometry. Tissue processing,
RNA extraction, and qRT-PCR assay set up were performed in separate de-
signated laboratory areas to prevent cross-contamination.
2.3. Primers
Using Primer3 software analysis available on the web [51], we selected
primer sequences to optimally hybridize and amplify target for qRT-PCR assay.
To avoid possible amplification of contaminating genomic DNA, primers were
designed so that each PCR product covered at least one intron. All the primers
used have been synthesized by Sigma-Genosys (The Woodlands, TX) and their
sequences are listed in Table 1.CIITApI Forward TACCACTGCACTCTGCTCCATG
Reverse GAACTGGTCGCAGTTGATG
CIITApIII Forward CCTGGCTCCACGCCCTG
Reverse GAACTGGTCGCAGTTGATG
CIITApIV Forward GAGCTGGCGGGAGGGAG
Reverse GAACTGGTCGCAGTTGATG
Fig. 1. Modulation of the expression of HLA-DRA, HLA-DQA1 and CIITA
genes following IFNα treatment. (a) Fold-change in the accumulation of mRNA
specific for HLA-DRA, HLA-DQA1 and CIITA, after ex vivo treatment with
IFNα in pancreatic islet tissue, B-LCLs, and DCs; and (b) with IFNγ in
pancreatic islets, as measured by qRT-PCR. The values used for the graph are the
mean values of triplicate measurements from at least two independent
experiments (n≥6).
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All reverse transcriptase reactions were performed using the RT System from
Promega (Madison,WI)with oligo-dTpriming, from1μg of total RNA. The qPCR
assay was performed in the Cepheid SmartCycler System (Sunnyvale, CA) using
cDNA from 10 ng of total RNA for each reaction. The QuantiTect SYBR Green
PCR Kit (Invitrogen) was used to perform all the reactions in presence of 0.2 μM
primers, in a total volume of 25 μl. Samples were amplified with a precycling hold
at 95 °C for 15 min, followed by 46 cycles of denaturation at 95 °C for 15 s,
annealing at 60 °C for 20 s (annealing at 57 °C for HLA-DQA1, CIITApI,
CIITApIII and CIITApIV), and extension at 72 °C for 30 s.
qRT-PCR reagent controls (reagent alone without RNA or cDNA) were
included in all the assays. For each assay specific for MHCII genes and CIITA,
one standard positive control (B-LCL NACR.0112, highly expressing MHCII
and CIITA genes) and one standard negative control (K562 cell line, not
expressing MHCII and CIITA genes at all) were added as well. Each assay was
run in triplicates and repeated at least twice to verify the results, and the mean
copy number was used for analysis. The standard deviation between assays was
not significant (b5%) for all transcripts studied. The relative amount of specific
transcripts was calculated as previously described [8]. To correct for sample to
sample variations in qRT-PCR efficiency and errors in sample quantitation, the
level of GAPDH expression was tested and used as a reference value. The
statistical significance of the fold differences between groups was calculated by
Student's t test. External standards were used to establish standard RealTime
PCR curves for quantifying copies of those transcripts that required an absolute,
comparative quantitation, such as different HLA-DQA1 alleles and different
CIITA transcripts. Each standard curve was obtained by using seven known
copy numbers of serially diluted (100 to 108 copies) plasmids containing HLA-
DQA1*01, HLA-DQA1*02, HLA-DQA1*03, HLA-DQA1*05, generic CIITA,
CIITApI, CIITApIII, or CIITApIV amplification product cloned in the pcR4
vector from Invitrogen.
3. Results
3.1. IFNα treatment of purified islets results in decreased
accumulation of HLA-DRA and HLA-DQA1 transcripts
To establish the effect of IFNα on the expression of MHCII
genes in pancreatic islet tissue relative to professional APCs, we
first evaluated the result of IFNα treatment on B-lymphoblastoid
cell line (B-LCLs), as an in vitro model of B cells.We examined a
total of five HLA-typed B-LCLs (Sample IDs BL-A, BL-B, BL-
C, BL-D and BL-E) that were first tested for their ability to up-
regulate MHCII expression after IFNγ stimulation [37]. Using
qRT-PCR assay, we observed in B-LCLs cultured for 5 days in
presence of IFNγ (1000 U/ml) a significant increase (Pb0.05) in
the accumulation of HLA-DRA and HLA-DQA1 transcripts re-
lative to untreated cells (data not shown). Next, to determine the
effects of IFNα treatment on gene expression of the B-LCLs, we
measured the level of mRNA specific for Interferon Regulatory
Factor 7 (IRF7), a gene upregulated by IFNα [52]. After 48 h of
IFNα stimulation (1000 U/ml), treated B-LCLs significantly
(Pb0.05) accumulated more transcripts for IRF7 relative to un-
treated cells confirming that the cells had undergone interferon
stimulation (data not shown). qRT-PCR analysis of the our set of
samples after 5 days of IFNα-treatment, revealed a significant
fold increase (Pb0.05) in the amount ofmRNA specific for HLA-
DRA, ranging from 1.3 to 2.1 (mean=1.6), and for HLA-DQA1,
ranging from 1.4 to 2.7 fold increase (mean=1.8) (Fig. 1, panel
A).
We then considered immature and differentiation-induced
human myeloid cells. Plastic adherent monocytes were obtainedfrom five healthy blood donors (sample IDs DC-A, DC-B, DC-
C, DC-D, and DC-E), cultured in either GM-CSF alone or GM-
CSF and IFNα, and total RNA was extracted. Using qRT-PCR
assay, DCs obtained from cultures with GM-CSF plus IFNα
showed the accumulation of a remarkable amount of transcripts
for IRF7 relative to monocytes treated only with GM-CSF (data
not shown). As expected [49,53], the qRT-PCR assay showed
an increase of 2.2 to 5.6 fold (mean=3.5) in the HLA-DRA
specific mRNA and of 1.9 to 5.9 fold (mean=4.3) in HLA-
DQA1 specific mRNA in cells after 6 days of stimulation with
GM-CSF and IFNα compared to control cells after 6 days of
stimulation with only GM-CSF (Pb0.05 for both genes) (Fig. 1,
panel A).
To determine the effect of IFNα treatment on gene expression
of the purified islets, we first examined by qRT-PCR the change in
the accumulation of IRF7. We observed that, similar to our pre-
vious results of microarray studies [8], after 48 h of IFNα stimu-
lation (1000 U/ml), all the samples of treated islets significantly
(Pb0.05) accumulatedmore IRF7 transcripts relative to untreated
islets (data not shown). However, the analysis of the expression of
MHCII and CIITA genes on the five different purified islet tissue
preparations (sample IDs IS-A, IS-B, IS-C, IS-D and IS-E)
produced results striking contrast with the above described results
from the study of B-LCLs and DCs. First, consistent with our
Table 2
qRT-PCR of HLA-DQA1 allele-specific mRNA accumulation in B-LCLs, DCs
and pancreatic islets, before and after IFNα treatment
Tissue Sample
ID
DQA1
allele
no IFN a + IFNα a Fold
change b
Index of inter-
allelic
variability
B-LCLs BL-A *01 1.06×104 1.57×104 ↑ 1.5 1.0
*02 1.42×104 2.07×104 ↑ 1.5
BL-B *01 1.17×104 2.00×104 ↑ 1.7 1.1
*03 2.61×104 4.84×104 ↑ 1.9
BL-C *01 1.37×104 3.91×104 ↑ 2.8 1.1
*05 1.18×104 2.92×104 ↑ 2.5
BL-D *02 1.06×104 1.65×104 ↑ 1.6 1.1
*05 8.12×103 1.43×104 ↑ 1.8
BL-E *03 1.11×104 1.74×104 ↑ 1.6 1.2
*05 1.71×104 2.23×104 ↑ 1.3
Dendritic
cells
DC-A *01 2.01×104 9.46×104 ↑ 4.7 1.4
*03 1.49×104 1.03×105 ↑ 6.9
DC-B *01 4.14×104 8.69×104 ↑ 2.1 1.2
*03 5.01×104 8.51×104 ↑ 1.7
DC-C *01 3.40×104 1.43×105 ↑ 4.2 1.3
*03 3.40×104 1.83×105 ↑ 5.4
DC-D *03 1.97×104 7.10×104 ↑ 3.6 1.1
*05 1.78×104 7.32×104 ↑ 4.1
Pancreatic
islets
IS-A *01 1.80×102 9.50×101 ↓ 1.9 1.2
*05 1.22×102 7.70×101 ↓ 1.6
IS-B *01 2.12×102 0 ↓ ≥212 ≥66
*03 3.85×102 1.20×102 ↓ 3.2
IS-C *01 3.57×102 1.71×102 ↓ 2.1 2.1
*05 2.76×102 6.20×101 ↓ 4.4
IS-D *02 1.34×102 1.29×102 ↓ 1.0 2.2
*03 1.70×102 7.40×101 ↓ 2.3
IS-E *01 3.80×101 1.80×101 ↓ 2.1 1.0
*03 1.01×102 4.80×101 ↓ 2.1
a Allele-specific mRNA accumulation measured in copy number per 10 ng of
total RNA. The values used for the table are the mean values of triplicate
measurements from at least two independent experiments (n≥6).
b Fold increase (↑) or fold decrease (↓) in each sample after IFNα treatment.
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MHCII genes in total RNA obtained from pancreatic islet sam-
ples, qRT-PCR showed significant baseline expression of HLA-
DRA and HLA-DQA1 transcripts in all untreated samples, repre-
senting about 1%of the relative amount found inNACR.0112, the
B-LCL used as positive control (data not shown). This result is
consonant with the expected low frequency of MHCII expressing
cells in the islet tissue compared with the high percentage of cells
expressing MHCII in the NACR.0112 population. As described
in detail inMaterials andmethods, the sensitivity of our qRT-PCR
assay for all the MHCII and CIITA transcripts was carefully
evaluated. For each sample analyzed, the qPCR assay was per-
formed in triplicates at least twice (from two distinct RT reactions)
and, after normalizations, the standard deviation between repli-
cate assays wasb5%. After 48 h of culture in presence of IFNα
there was a 1.4 to 2.6 fold decrease (mean=1.9) in the amount of
HLA-DRA-specificmRNA in treated islets versus untreated islets
as well as a 1.5 to 5.0 fold decrease (mean=2.6) of HLA-DQA1-
specific mRNA (Pb0.05 for both genes) (Fig. 1, panel A). In
control experiments, the effect of IFNγ-stimulation on the
pancreatic islet samples induced a significant increase (Pb0.05)
in the amount of HLA-DRA and HLA-DQA1 transcripts after
48 h of stimulation (Fig. 1, panel B).
3.2. The regulation of the HLA-DQA1 gene by IFNα in islet
tissue is allele-specific
Out of 15 RNA samples from different cells and tissues anal-
yzed in our study, 14were prepared fromHLAheterozygous lines
or donors that carried two different HLA-DQA1 alleles (Table 2).
Using qRT-PCR technology with DQA1 allele-specific primers
and external standards, we found that the absolute levels of
transcripts (expressed in mRNA copy number per 10 ng of total
RNA and normalized per GAPDH amount) varied considerably
after IFNα treatment for each of the HLA-DQA1 alleles ex-
pressed by the different heterozygous samples, according to their
lineage (Table 2). Namely, we observed a statistically significant
(Pb0.05) decrease of the copy number of all of the HLA-DQA1
allele-specific transcripts in the islet tissue samples, and increase
of the copy number of all of the HLA-DQA1 allele-specific
transcripts in B-LCLs and DCs samples. To better conceptualize
the relationship between transcript levels for different HLA-
DQA1 alleles expressed in heterozygous cells, we established an
“index of inter-allelic variability” by calculating the ratio between
the after-stimulation fold-change in the copy number of one
allele-specific transcript and the after-stimulation fold-change in
the copy number of the other allele-specific transcript. For exam-
ple, in BL-A, after IFNα stimulation, there is a 1.5 fold increase in
the expression of DQA1*02 allele as well as a coordinate and
comparable 1.5 fold increase in the expression of DQA1*01
allele. The ratio between the fold-changes in the accumulation of
allele-specific mRNA after 5 days of IFNα treatment in this cell
line was then equal to one (see Table 2). In this instance, the index
suggests an absence of inter-allelic variability. The index of inter-
allelic variability in the other B-LCLs suggests that there is very
little or no inter allelic variability in the expression of the DQA1
locus at the level of mRNA accumulation after 5 days of stim-ulation with IFNα in B-LCLs (Table 2). Similar results were
obtained in the analysis of the accumulation of transcripts specific
for the different DQA1 alleles in DCs derived from the four
heterozygous individuals (DC-B, DC-C, DC-D, and DC-E).
Specifically, the increase of the level of DQA1 transcripts in DCs
from cultureswithGM-CSF and IFNα vs.monocytes treated only
with GM-CSF is comparable for both the alleles (Table 2). The
observed coordinate increase of the DQA1 alleles in the same
individual showed a ratio or index of inter-allelic variability of 1±
0.4.
All five pancreatic islet tissue samples were obtained from
donors heterozygous at the HLA-DQA1 locus. In our control
experiments, whenHLA-DQA1 allele-specificmRNAcopy num-
ber was examined in each islet sample treated ex vivo with IFNγ,
we found a coordinate increase of the level of both the allelic
transcript with an index of inter-allelic variability of 1±0.6 (data
not shown). A distinctly different coordinate, but unbalanced
decrease of the DQA1 allele-specific mRNA in the same sample
was found in experiments after 48 h of IFNα ex vivo stimulation
of islets. The variation in the level of HLA-DQA1 allele-specific
mRNA in each of the heterozygous samples after IFNα treatment
showed notably different values in three of them, indicating a
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(see Table 2). Noteworthy, in islet sample IS-B, the index of inter-
allelic variability was ≥66. Repeat determinations of the allele-
specific variation of the level of DQA1 specific mRNA after
treatment with IFNα in this sample revealed that, while the
amount of DQA1*03-transcript decreased of 3.2 fold after IFNα
treatment, the amount of transcript for DQA1*01-allele became
undetectable in the treated sample compared with the untreated
control, where the transcript was consistently present.
3.3. The expression of MHCII genes in human islets is
accompanied by the expression of the CIITApIV isoform
With the goal of studying the expression of CIITA in relation
to the expression of MHCII genes we next analyzed the pre-
sence of transcripts specific for this gene in ex vivo cultured
pancreatic islets, B-LCLs and myeloid lineage cells. First, for
Real-Time RT-PCR we used a pair of generic CIITA primers
encompassing sequences common to all the three known human
isoforms of the transactivator. Our experiments allowed the
detection of specific RNA for CIITA in all our pancreatic islets
samples in an amount commensurate with the MHCII mRNA
level (data not shown). Using primers that specifically amplified
the three different human CIITA isoforms (CIITApI, CIITApIII,
and CIITApIV) we found that∼90% of the CIITA mRNA found
in samples from pancreatic islets was CIITApIV, while tran-
scripts for CIITApI and CIITApIII accounted for∼2% and∼8%,
respectively, of the total. In agreement with as previously
described (reviewed in [34]) our qRT-PCR assay showed that
the CIITA mRNA detected in BL samples was for the most part
represented by CIITApIII transcripts, constituting ∼75% of the
total transcripts, and in DC samples the CIITA mRNA was
mainly composed of CIITApI transcripts representing ∼80% of
the total.
Lastly, we measured the variation in the amount of CIITA
specific mRNA in all samples included in our study following
stimulation with IFNα. In the five pancreatic islet samples after
treatment with IFNα, corresponding to the observed decrease of
MHCII messages, we detected a decrease in the copy number of
CIITA mRNA ranging from 1.3 to 2.8 fold (mean=2.1) (Fig. 1,
panel A).
In the BL samples after 5 days of IFNα stimulation, we
observed an increase of the total level of CIITA transcripts that
ranged from 1.4 to 2.4 fold (mean=1.8) (Fig. 1, panel A).
Analysis of the CIITA isoforms within the expanded transcript
pool showed that CIITApIII and CIITApIV isoforms accounted
for 75% and 25% of the increase, respectively. The CIITApI
pool size did not change (data not shown).
The difference in the accumulation of CIITA specific mRNA
in DCs grown from cultures with GM-CSF and IFNα versus
monocytes treated only with GM-CSF, ranged from 2.6 to 5.1
times (mean=4.1) higher in IFNα-treated cells relative to cells
treated with GM-CSF alone (Fig. 1, panel A). Analysis of the
CIITA isoforms within the expanded transcript pool showed
that CIITApI transcripts represented 45% of the increased
amounts, with CIITApIV and CIITApIII accounting for 35%
and 20%, respectively, of the new transcripts.In the experiments with IFNγ, measurements of the accu-
mulation of CIITA transcripts in the pancreatic islet samples
after treatment showed the following: again, similar to the effect
of IFNγ stimulation on MHCII messages observed in IS sam-
ples, after 48 h there was a significant (Pb0.05) strong increase
in the amount of CIITA-specific transcript in treated versus
untreated islets, ranging from 7.5 and 40.4 fold (mean=16.9) in
the different islet samples studied (Fig. 1, panel B). This
increase was mostly due to the accumulation of the CIITApIV
isoform.
4. Discussion
The central findings of the present study are first that there is
a remarkable lineage-specific regulation of the expression of
MHCII genes driven by exposure of cells to IFNα, with de-
crease in the accumulation of MHCII transcripts in pancreatic
islets tissue and an increase in dendritic and B cells. Second, the
differences in regulation are mediated by alterations in the
expression of the MHCII transcriptional activator CIITA. Third,
the expression of MHCII genes in human islets is primarily
accompanied by the expression of the CIITApIV isoform in
absence of ex vivo IFNγ stimulation, similar to that described in
non professional APCs such as thymus epithelial cells [38].
Fourth, the extent of the downregulation by IFNα differs among
different HLA-DQA1 alleles, consistent with the polymorphism
of the regulatory sequences of this gene [43].
A direct quantitative correlation between the levels of mRNA
specific for CIITA and for MHCII genes has been reported in
several studies [35,36,54,55]. The present work extends this
information by the direct measurement of the accumulation of
RNA specific for MHCII genes and for the different CIITA
isotypes in B cells, DCs and pancreatic islet tissue after IFNα
induction. Our findings highlight the distinct regulatory patterns
in different cell lineages and differentiation stages. In agreement
with our previous data [8], we confirmed that in human islet tissue
IFNα treatment induces the decrease of HLA-DRA and HLA-
DQA1 expression. It is widely accepted that IFNγ induced
MHCII expression is controlled by the induction of CIITA [33].
Similarly, in our experiments with IFNα stimulation, the CIITA
expression pattern correlates with that of MHCII molecules: after
treatment it increases in B cell lines and DCs and decreases in
pancreatic islets.
The pattern of theCIITApIVisoform expression, in the absence
of ex vivo IFNγ stimulation, is similar to that described in non
professional APCs, andmight reproduce the situation described in
diabetic pancreata, representing an excellent model system for the
study of the role of CD4+ T cells in the organ specific auto-
immunity [20,25]. The IFNα-induced reduction of MHCII
expression in islets is consistent with the observed reduction of
immunogenicity and increase of allograft survival during the
transplant rejection observed in different systems following IFNα
treatment. Given that clinical islet preparations have significant in
vitro allostimulatory capacity [24], the present data are highly
relevant in transplantation since the ex vivo manipulation of
expression of MHCII molecules in pancreatic islets destined for
transplantation might reduce their immunogenicity and increase
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suppressive drugs.
Our finding that CIITApIV is the dominant form within islet
tissue suggests that the MHCII transcripts detected do not
originate primarily fromprofessionalAPCs in the islet preparation
and likely reflect the presence of non professional APCs [20,27].
Because of the minimal amount of CIITApI and CIITApIII
transcripts detected in the RNA from islets samples, we feel
confident to exclude that the MHCII transcripts we identify in our
preparations are only derived from the DCs or the lymphocytes
presents in the tissue. Our data do not exclude that islet β cells
themselves or islet ECs expressMHCII. The pancreatic islets used
in our experiments displayed a broad array of transcripts specific
for endothelial proteins, included cadherin-1, endothelin-1 and
endoglin (data not shown). In addition, the analysis of gene
expression profiling data of human islet tissue versus the same
islet tissue after 48 h of culture in presence of IFNα [8], showed no
change in the level of endothelial restricted transcripts.
The expression of MHCII, as mediated by CIITApIV, has
already been demonstrated in freshly isolated microvascular ECs
from kidney [39], vascular ECs [36], and thymic epithelial cells
[38]. In the latter case, there are strong suggestions that the
expression of CIITApIV and MHCII is IFNγ-presence indepen-
dent and is maintained if the cells are cultured as reaggregated
thymus organ cultures. It has been suggested that this situation is
due to a stimulus perceived from the cells only in vivo or in three-
dimensional reaggregates, such as cell–cell interactions. This
condition seems to be pertinent to the organ culture of pancreatic
islets andwould also explain the different results obtained in other
kind of preparations.
The differences in HLA-DRA, HLA-DQA1 and CIITA
expression within islet tissue observed following treatment with
IFNα versus IFNγmay be a reflection of a unique mechanism by
which the limited amount of islet tissue in situ could be protected
from damage caused by inflammation initiated by the innate arm
of the immune response. The expression of type 1 interferons (e.g.,
alpha) is induced by viral challenges through the Toll-like re-
ceptors expressed on macrophages and dendritic cells. Type II
interferon production is inducedmore specifically and restricted to
MHC bound peptide antigen-stimulated T cells or superantigen
stimulated Tcells of the adaptive arm of the immune response [56].
In contrast to the reported improvement of murine and human
T1Dwith IFNα administration [5–7], it iswell accepted that IFNα
can cause autoimmunity [1]. It has been shown that circulating
IFNα induces increase of the expression of MHCII molecules in
professional APCs from hepatitis C patients treated with this
cytokine [57] and in SLE patients [58]. The data we present in this
paper, documenting lineage differences in regulation of MHCII,
may represent the first element of a more complex explanation for
the IFNα/immunity paradox and for the relative heterogeneity in
the clinical responses. The concept of cell lineage specific dif-
ferences in regulation ofMHCII suggests that diseases induced by
IFNα administration are driven by presentation of autoantigens by
an axis of dendritic and B cells. Organ-specific autoimmunity, on
the other hand, could be preferentially driven by allele-specific
regulation of genes associated with autoimmune diseases sus-
ceptibility (such as DQA1 with T1D).In human islet tissue we found that, differently from what
occurs in B-LCL and monocytes, there is a clear difference in the
IFNα-induced variation of the amount of the allele-specific
mRNA. While it is widely accepted that T1D is caused by
autoimmune destruction of the insulin-producing β-cells of the
pancreatic islets, questions remain unanswered of where and
when naive islet-reactive T cells first encounter antigen and be-
come stimulated. One possible setting is within the islets, where
autoantigens are presented either by the β-cells that synthesize
them or byAPCs in the vicinity. The present findings demonstrate
a distinct pattern of the regulation of the expression of HLA-
DQA1 alleles in islet tissue. Such a pattern of regulation cor-
responds to allele-specific differential expression of the T1D-
associated molecule HLA-DQA1 following an environmental
stimulus as IFNα (possibly associated to viral infection, the most
commonly indicated trigger of T1D development) in APCs re-
sident in the islets. The distinct regulation ofMHCII in islet tissue
demonstrated in the present study suggests the possibility that the
induced expression of MHCII–peptide complexes by the islets
differs both quantitatively and qualitatively from that present in
the thymus during the generation of central tolerance and perhaps
during establishment of peripheral tolerance. More specifically,
we propose that allele-specific differential regulation of the
expression of the T1D-associated molecule HLA-DQA1 – the
result of a particular microenvironment in the islets – results in an
increased density of MHC–peptide complexes on the surface of
islet cells (including ECs) which is qualitatively different from
that involved in the selection of the T cell repertoire.
At the moment, we are concentrating our effort to define the
cell type expressing MHCII in the islet tissue, both via in situ
RNA hybridization and immunohistochemistry. Because of the
superior availability both of samples (purified islets) and re-
agents (i.e., antibodies towards IA and IE antigens suitable for
immunohistochemistry), we are currently moving to the mouse
model.
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